TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16477553

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone-free intervention at Caen Hospital
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Control hospitals (three university hospitals)
Number of subjects: 1093
Study: 16784179

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14555256

Group type: EXPERIMENTAL
Intervention: Jumping program (25 jumps/day from a 45‐cm box, 5 days/week for 12 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Jumping program
Number of subjects: 54
Study: 11456252

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.50%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Betaxolol HCL 0.50%
Number of subjects: 40
Study: 8953683

Group type: EXPERIMENTAL
Intervention: Biapenem 500 mg every 8 h
Number of subjects: 118

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg/500 mg every 6 h
Number of subjects: 118
Study: 2044986

Group type: EXPERIMENTAL
Intervention: Money management service (n = 40)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Customary screening by the Office of the Public Guardian or Adult Protective Services (n = 23)
Number of subjects: 63
Study: 6793920

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate 1.8 g
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 31415482

Group type: EXPERIMENTAL
Intervention: Educational intervention (narrated, educational presentation by computer)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 48
Study: 27398685

Group type: EXPERIMENTAL
Intervention: High-pull specific (HPS)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cycle+HPS
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: WBV+HPS
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study: 25902814

Group type: EXPERIMENTAL
Intervention: Predominantly menstrual migraine (MM)
Number of subjects: 1697

Group type: EXPERIMENTAL
Intervention: Menstrually-associated migraine (MAM)
Number of subjects: 1697

Group type: COMPARATOR
Intervention: Menstrually-unrelated migraine (MUM)
Number of subjects: 1697
Study: 23425564

Group type: EXPERIMENTAL
Intervention: Everolimus (10mg/day) + Exemestane (25mg/day)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Exemestane only (placebo)
Number of subjects: 724
Study: 21051765

Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 20028263

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 59

Group type: COMPARATOR
Intervention: Verapamil 0.25%
Number of subjects: 59
Study: 17465257

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin
Number of subjects: 95

Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin alternating with paclitaxel/cisplatin
Number of subjects: 95
Study: 14997127

Group type: EXPERIMENTAL
Intervention: Endoscopic ligation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nadolol
Number of subjects: 100
Study: 11528536

Group type: EXPERIMENTAL
Intervention: General characteristics and content of neuropsychological reports
Number of subjects: 414
Study: 9292756

Group type: EXPERIMENTAL
Intervention: Meal 1 (121g carbohydrate, 16g protein, 48g fat)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Meal 2 (70g carbohydrate, 16g protein, 70g fat)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Meal 3 (50g carbohydrate, 14g protein, 80g fat)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Meal 4 (0g carbohydrate, 0g protein, 108g fat)
Number of subjects: 8
Study: 8084248

Group type: EXPERIMENTAL
Intervention: Oral protein load in Group I (reflux patients)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral protein load in Group II (urinary infection patients)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral protein load in Group III (healthy controls)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Control period in Group I (reflux patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control period in Group II (urinary infection patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control period in Group III (healthy controls)
Number of subjects: 24
Study: 3318465

Group type: EXPERIMENTAL
Intervention: Chorionic villi sampling
Number of subjects: 61

Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 61
Study: 31924473

Group type: EXPERIMENTAL
Intervention: Spinal morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posterior quadratus lumborum block
Number of subjects: 0
Study: 30303839

Group type: EXPERIMENTAL
Intervention: Physicians provided with vignettes of hypothetical patients
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Factors unrelated to severity of illness (ICU bed availability mentioned vs. unmentioned)
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Factors unrelated to severity of illness (family presence vs. unmentioned)
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Patient's age
Number of subjects: 1223
Study: 27882820

Group type: EXPERIMENTAL
Intervention: AXL1717 (AXL) 300 or 400 mg daily BID
Number of subjects: 99

Group type: COMPARATOR
Intervention: Docetaxel (DCT) 75 mg/m2 in three-week cycles
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: AXL1717 (AXL)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Docetaxel (DCT)
Number of subjects: 99
Study: 26037479

Group type: EXPERIMENTAL
Intervention: Interactive device with visual and acoustic instructions for ALS workflow measures
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard CPR equipment
Number of subjects: 42
Study: 24386809

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT) via nasal cannula, administered continuously every day for one year.
Number of subjects: 96
Study: 21481871

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (SET) on top of best medical treatment (BMT) for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (SET)
Number of subjects: 40
Study: 19190265

Group type: EXPERIMENTAL
Intervention: High-fat diet (65 energy-% Fat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-carbohydrate diet (65 energy-% CHO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise (1 h of one-legged knee extensor exercise)
Number of subjects: 12
Study: 16923003

Group type: EXPERIMENTAL
Intervention: VRR algorithm (INSIGNIA pacemakers)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Fixed rate stimulation at 60 ppm (Control)
Number of subjects: 58
Study: 15532380

Group type: EXPERIMENTAL
Intervention: Carvedilol (24.4 +/- 2.0 mg/day) + Fosinopril (2.5-40 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atenolol (44.1 +/- 5.1 mg/day) + Fosinopril (2.5-40 mg/day)
Number of subjects: 50
Study: 12036674

Group type: EXPERIMENTAL
Intervention: Clinical measurements by endocrinologist and ophthalmologist using Krahn exophthalmometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computed tomography (CT) scans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical measurements by different clinicians
Number of subjects: 0
Study: 9791321

Group type: EXPERIMENTAL
Intervention: Supervised fitness walking program
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study: 8608070

Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 66
Study: 2670719

Group type: EXPERIMENTAL
Intervention: Magaldrate (antacid poor in aluminum)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Compound M 70 (antacid rich in aluminum)
Number of subjects: 19
Study: 791444

Group type: EXPERIMENTAL
Intervention: Depilatory cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine shaving
Number of subjects: 0
Study: 31526767

Group type: EXPERIMENTAL
Intervention: Levodopa medication (on medication)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Training off levodopa medication (off medication)
Number of subjects: 23
Study: 31172719

Group type: EXPERIMENTAL
Intervention: benralizumab Q4W
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: benralizumab Q8W
Number of subjects: 122

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 122
Study: 26626800

Group type: EXPERIMENTAL
Intervention: S-1 (40-60 mg/m2 twice daily) for 2 weeks, followed by S-1 and oxaliplatin (100 mg/m2) for 8 cycles
Number of subjects: 63
Study: 25223844

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), manualized exposure-based
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) add-on study
Number of subjects: 231
Study: 23732258

Group type: EXPERIMENTAL
Intervention: Bascom cleft lift
Number of subjects: 122

Group type: COMPARATOR
Intervention: Limberg flap
Number of subjects: 122
Study: 21831418

Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel doublet chemotherapy (4 cycles: 3 weeks on treatment, 1 week off; carboplatin on day 1, paclitaxel on days 1, 8, and 15)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Vinorelbine or gemcitabine monotherapy (5 cycles: 2 weeks on treatment, 1 week off)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy
Number of subjects: 451
Study: 19389795

Group type: EXPERIMENTAL
Intervention: Hepatectomy followed by 12 cycles of modified FOLFOX6 (mFOLFOX6) regimen
Number of subjects: 300

Group type: COMPARATOR
Intervention: Hepatectomy alone
Number of subjects: 300
Study: 16713809

Group type: EXPERIMENTAL
Intervention: Immediate Loaded (IL) group (n=24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Immediate Provisionalized (IP) group (n=24)
Number of subjects: 48
Study: 14670577

Group type: EXPERIMENTAL
Intervention: Right hemisphere (RH) patients
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Left hemisphere (LH) patients
Number of subjects: 118

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 118
Study: 10722036

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (66 mg/kg per hour)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no ascorbic acid)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study: 8818095

Group type: EXPERIMENTAL
Intervention: Lidocaine containing adhesive tape (LT), applied 30 min before venipuncture
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (no LT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Lidocaine containing adhesive tape (LT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Expert group (with LT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Novice group (with LT)
Number of subjects: 145
Study: 1333105

Group type: EXPERIMENTAL
Intervention: Unfractionated (UF) heparin 5000 IU three times daily for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low molecular weight (LMW) heparin (CY 216 D) 3100 IU once daily for 10 days
Number of subjects: 0
Study: 6737408

Group type: EXPERIMENTAL
Intervention: Three interventions for mother and toddler problems
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31141834

Group type: EXPERIMENTAL
Intervention: Chicken meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pork meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beef meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control meal (egg white and pea)
Number of subjects: 0
Study: 27687678

Group type: EXPERIMENTAL
Intervention: 20 mg/m2 cisplatin on 5 days every 4 weeks (group A)
Number of subjects: 170

Group type: COMPARATOR
Intervention: 30-40 mg/m2 cisplatin weekly (group B)
Number of subjects: 170
Study: 25912677

Group type: EXPERIMENTAL
Intervention: Mindfulness cognitive training group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mindfulness interoceptive training group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non‐intervention control group
Number of subjects: 45
Study: 23887901

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study: 21810108

Group type: EXPERIMENTAL
Intervention: Guided self-help (GSH) intervention provided by primary care graduate mental health workers (PCGMHWs)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Waiting list control (delayed treatment group)
Number of subjects: 122
Study: 19627940

Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (RAGT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Regular physiotherapy
Number of subjects: 67
Study: 16704994

Group type: EXPERIMENTAL
Intervention: Soft-tip catheter
Number of subjects: 540

Group type: COMPARATOR
Intervention: Hard-tip catheter
Number of subjects: 540
Study: 16248380

Group type: EXPERIMENTAL
Intervention: QGS (quantitative electrocardiography-gated myocardial perfusion single photon emission computed tomography)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: QGS
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Plasma BNP concentrations
Number of subjects: 46
Study: 10912691

Group type: EXPERIMENTAL
Intervention: Topical adrenaline application after myringotomy before tympanostomy tube placement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline application to contralateral ear after myringotomy
Number of subjects: 50
Study: 9060957

Group type: EXPERIMENTAL
Intervention: Self-examination instruction group (133375 women)
Number of subjects: 267040

Group type: COMPARATOR
Intervention: Control group (133665 women)
Number of subjects: 267040

Group type: EXPERIMENTAL
Intervention: Self-examination instruction group
Number of subjects: 267040

Group type: COMPARATOR
Intervention: Self-examination instruction group and Control group
Number of subjects: 267040
Study: 8259772

Group type: EXPERIMENTAL
Intervention: Etidronate therapy (400 mg daily for 14 days, phosphate 1.0 g twice daily for 3 days, calcium 500 mg daily for the remainder of each 91-day cycle)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Etidronate therapy
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Open-label intermittent cyclic etidronate therapy
Number of subjects: 423

Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 423
Study: 3897204

Group type: EXPERIMENTAL
Intervention: Fluoxetine (55 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Amitriptyline (159 mg/day)
Number of subjects: 44
Study: 2447297

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31818628

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg once daily for 3 weeks)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Placebo (for 3 weeks)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 646

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 646
Study: 29885375

Group type: EXPERIMENTAL
Intervention: Age <65 years
Number of subjects: 6159

Group type: EXPERIMENTAL
Intervention: Age 65-74 years
Number of subjects: 6159

Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 6159
Study: 28177189

Group type: EXPERIMENTAL
Intervention: High cortisol (c. 1400 nM) with high insulin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High cortisol (c. 1400 nM) with low insulin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High cortisol (c. 1400 nM) with adrenaline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High cortisol (c. 1400 nM) in vitro with insulin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High cortisol (c. 1400 nM) in vitro without insulin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High cortisol (c. 1400 nM)
Number of subjects: 20
Study: 26095467

Group type: COMPARATOR
Intervention: Limited screening (basic blood testing, chest radiography, and screening for breast, cervical, and prostate cancer)
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Limited screening plus CT
Number of subjects: 854

Group type: COMPARATOR
Intervention: Limited screening
Number of subjects: 854
Study: 24124684

Group type: EXPERIMENTAL
Intervention: One-stop diagnosis and treatment group (CTU 3-D reconstruction, ultrasound and radiology guided puncture followed by PCNL)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (PCNL without radiological guidance)
Number of subjects: 210
Study: 21139017

Group type: EXPERIMENTAL
Intervention: Video calls
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ordinary mobile phone calls
Number of subjects: 180
Study: 18679073

Group type: EXPERIMENTAL
Intervention: Probiotics (Ecologic 641, containing four Lactobacillus and two Bifidobacillus strains)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16970649

Group type: EXPERIMENTAL
Intervention: Olfactory stimulation with black pepper oil (BPO)
Number of subjects: 105
Study: 14642409

Group type: EXPERIMENTAL
Intervention: Standard methionine load
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 18
Study: 12212157

Group type: EXPERIMENTAL
Intervention: External irradiation and after-load intracavitary radiation in combination with traditional Chinese medicine (EIAIRC)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: External irradiation plus traditional Chinese medicine (EIC)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard radiotherapy (SRT)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM)
Number of subjects: 163
Study: 8837569

Group type: COMPARATOR
Intervention: No medication (ischemia-none group)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Nitroglycerin (ischemia-NTG group)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Nifedipine (ischemia-nifedipine group)
Number of subjects: 131
Study: 1450659

Group type: EXPERIMENTAL
Intervention: lodoxamide 0.1% ophthalmic solution
Number of subjects: 135

Group type: COMPARATOR
Intervention: sodium cromoglycate 2% ophthalmic solution
Number of subjects: 135
Study: 6375407

Group type: EXPERIMENTAL
Intervention: 100 mg Doxycycline (DX)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Doxycycline (DX)
Number of subjects: 44
Study: 30891845

Group type: EXPERIMENTAL
Intervention: ATP provocation (A-P group)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Pacing (P-A group)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Combined approach (A-P and P-A groups)
Number of subjects: 107
Study: 29568206

Group type: EXPERIMENTAL
Intervention: Low-FODMAP rye bread
Number of subjects: 7

Group type: COMPARATOR
Intervention: Regular rye bread
Number of subjects: 7
Study: 27435790

Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC) and Laparoscopic cholecystectomy (LC)
Number of subjects: 106
Study: 23845740

Group type: COMPARATOR
Intervention: Metformin (1700 mg/die)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Metformin (1700 mg/die) plus low-dose spironolactone (25 mg/die)
Number of subjects: 56
Study: 22830441

Group type: EXPERIMENTAL
Intervention: DDD-70
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: DDDR-40
Number of subjects: 1433

Group type: COMPARATOR
Intervention: DDD-40 (control arm)
Number of subjects: 1433
Study: 20148739

Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metformin + Lifestyle modification
Number of subjects: 30
Study: 18506845

Group type: EXPERIMENTAL
Intervention: Fine-scale curvature measurement in OA population
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Coarse-scale curvature measurement in OA population
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Fine-scale curvature measurement in healthy and borderline OA populations (longitudinal study)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Coarse-scale curvature measurement in severe OA populations (longitudinal study)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Fine-scale curvature prediction in healthy individuals at baseline
Number of subjects: 288
Study: 15960556

Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 0
Study: 11926427

Group type: EXPERIMENTAL
Intervention: Health Kinesiology muscle test (verum)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (placebo bottles)
Number of subjects: 7
Study: 9932655

Group type: EXPERIMENTAL
Intervention: 33 mmol/L bicarbonate solution
Number of subjects: 33

Group type: COMPARATOR
Intervention: 40 mmol/L lactate solution
Number of subjects: 33
Study: 7708260

Group type: EXPERIMENTAL
Intervention: Ultrafiltration rate of 60 ml/min with dialysate calcium concentration of 1.63 mmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrafiltration rate of 100 ml/min with dialysate calcium concentration of 1.63 mmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion rate of 2.5 l/h with dialysate calcium concentration of 1.63 mmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion rate of 5 l/h with dialysate calcium concentration of 1.63 mmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion rate of 2.5 l/h with dialysate calcium concentration of 1.5 mmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion rate of 5 l/h with dialysate calcium concentration of 1.5 mmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion rate of 2.5 l/h with dialysate calcium concentration of 1.25 mmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion rate of 5 l/h with dialysate calcium concentration of 1.25 mmol/l
Number of subjects: 0
Study: 2658462

Group type: EXPERIMENTAL
Intervention: 0.2% sodium hyaluronate eye drops
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate eye drops
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate treatment (both concentrations)
Number of subjects: 20